Shares of Alivus Lifesciences rose 0.50% to Rs 1,038.30 on the BSE.

According to an exchange filing, the engagement includes a major order worth Rs 3.60 crore for Microsoft Select Plus perpetual licenses. While the licenses will be billed directly by the Licensing Solution Partner, DEVIT played a key advisory role in aligning Alivus Lifesciences’ IT infrastructure with the appropriate Microsoft licensing model. This highlights DEVIT’s capability in managing complex enterprise IT requirements and supporting clients in their digital transformation initiatives.

In addition, DEVIT secured a direct order worth Rs 80 lakh from Alivus Lifesciences for a suite of enterprise software solutions. This includes products from Microsoft, Zoho, Adobe, and TeamViewer, underscoring the company’s ability to deliver integrated, multi-product IT solutions tailored to specific business needs.

Dev Information Technology (DEV IT) is a technology solution provider helping companies in their digital transformation from advisory to execution, backed by expert applications and infrastructure management.

Alivus Life Sciences Limited (Formerly Glenmark Life Sciences is a leading developer and manufacturer of select, high-value, non-commoditized, active pharmaceutical ingredients (APIs) in chronic therapeutic areas such as cardiovascular disease, central nervous system disease, pain management and diabetes.

Shares of Dev Information Technology shed 0.33% to Rs 121.40 on the BSE.